JGC
UNCY icon

J. Goldman & Co’s Unicycive Therapeutics UNCY Stock Holding History

J. Goldman & Co’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Buy
+327,345
New +$2.41M 0.04% 391

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

J. Goldman & Co's UNCY Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Unicycive Therapeutics (UNCY) in Q2 2026: 327,345 shares worth $1.54M. The stake represents 0.04% of the portfolio and ranks #391 among its holdings.

73 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • J. Goldman & Co held 327,345 shares of Unicycive Therapeutics worth $1.54M as of Q2 2026.
  • Unicycive Therapeutics was a new J. Goldman & Co position in Q2 2026.
  • Unicycive Therapeutics made up 0.04% of J. Goldman & Co's portfolio in Q2 2026, its #391 holding.
  • 73 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.